Results 211 to 220 of about 326,995 (379)

Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment. [PDF]

Front Med (Lausanne), 2022
Delfanti G, Dellabona P, Casorati G, Fedeli M.   +3 more
europepmc   +1 more source

Four cases of oral cancer treated with adoptive immunotherapy (LAK therapy) and radiotherapy.

, 1996
湯川 善弘, 笹倉 裕一, 小瀬 晃, 篠塚 和明, 松本 剛一, 小堀 実, 伊吹 千夏, 李 宇錫, 新藤 潤一, 渡辺 是久   +9 more
openalex   +2 more sources

Adoptive cell transfer as personalized immunotherapy for human cancer

Science, 2015
S. Rosenberg, N. Restifo
semanticscholar   +1 more source

A Nano‐Electro‐Platform Enabling Evolutionary Screening and Remodeling of Tumor Cells for Metastasis Inhibition

Advanced Science, EarlyView.
The nano‐electro‐platform achieves non‐destructive evolutionary screening and electro‐remodeling of tumor cells to generate extracellular vesicles with enhanced tumor‐targeting and therapeutic functions. These extracellular vesicles demonstrate remarkable efficacy in activating both macrophages and T cells, thereby orchestrating a potent immune ...
Feng Liu, Hong Sun, Bing Liu, Jing Zhang, Chengbao Wu, Shi Yan, Chengzheng Tai, Yihang Tong, Rongtai Su, Xiaowei Xiang, Han Wu, Fuqi Yao, Kuan Yang, Dedong Yin, Yuqiong Wang, Ao Xiao, Long Cheng, Xi Chen, Nan Wu, Zaizai Dong, Lingqian Chang   +20 more
wiley   +1 more source

A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes. [PDF]

Gastro Hep Adv, 2022
Leone V, Peschke K, Reichert M.
europepmc   +1 more source

Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction [PDF]

, 2003
William Ho, Joseph N. Blattman, Michelle L. Dossett, Cassian Yee, Philip D. Greenberg   +4 more
openalex   +1 more source

CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade

Advanced Science, EarlyView.
This study demonstrates that engineering CAR T cells to express CXCL13 enhances their antitumor efficacy and significantly improves responsiveness to PD‐1 immune checkpoint blockade. CXCL13 promotes T cell persistence, and resistance to early exhaustion via the AKT‐mTOR pathway.
Yang Zhou, Wenli Zhao, Yihan Zhu, Hongyan Liu, Yicheng Sun, Zhengrong Gong, Xuanyi Li, Ziying Liu, Kang Wen, Yicheng Wang, Jie Ren, Ruipei Xiao, Ling Jiang, Yanfeng Hu, Enguang Bi, Xiaoyong Zhang   +15 more
wiley   +1 more source

Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy. [PDF]

JCI Insight, 2022
Hu L, Chen L, Xiao Z, Zheng X, Chen Y, Xian N, Cho C, Luo L, Huang G, Chen L.   +9 more
europepmc   +1 more source

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

Molecular Therapy: Methods & Clinical Development, 2018
Zhongzhen Yi, Brooke Prinzing, Felicia Cao, S. Gottschalk, Giedre Krenciute   +4 more
semanticscholar   +1 more source

Salvage esophagectomy for unresectable locally advanced esophageal squamous cell carcinoma: Significant or not?

Annals of Gastroenterological Surgery, EarlyView.
Abstract We reviewed the current status and perspectives on salvage esophagectomy for initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in the era of minimally invasive surgery and immunotherapy. Although the standard treatment for these patients is definitive chemoradiotherapy (CRT), the complete response rate to CRT ...
Hiroshi Saeki, Makoto Sakai, Takayoshi Watanabe, Makoto Sohda, Ken Shirabe   +4 more
wiley   +1 more source